Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma. [electronic resource]
Producer: 20140127Description: 324-37 p. digitalISSN:- 2159-8290
- Animals
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Apoptosis -- drug effects
- Biphenyl Compounds -- administration & dosage
- Carcinoma, Squamous Cell -- drug therapy
- Cell Cycle Proteins -- genetics
- Cell Line, Tumor
- Drug Synergism
- F-Box Proteins -- genetics
- F-Box-WD Repeat-Containing Protein 7
- Histone Deacetylase Inhibitors -- administration & dosage
- Histone Deacetylases -- genetics
- Humans
- Hydroxamic Acids -- administration & dosage
- Mice
- Mice, Nude
- Myeloid Cell Leukemia Sequence 1 Protein -- genetics
- Nitrophenols -- administration & dosage
- Piperazines -- administration & dosage
- Proto-Oncogene Proteins c-bcl-2 -- antagonists & inhibitors
- Sulfonamides -- administration & dosage
- Transfection
- Ubiquitin-Protein Ligases -- genetics
- Vorinostat
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.